Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05939674 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 12, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jun 2024 to Feb 2026
    • Enrollment target: 22 to 24
    • Study completion date: Jun 2024 to Jun 2026
    v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 2023 to Sep 19, 2023
    v3
  3. Secondary endpoints: details revised at 2 of 3 entriesv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Remimazolam is a medication that has the advantage of a short half-life and reversibility with flumazenil. In clinical situations, the use of flumazenil for the reversal of sedation is common, but there is no precise indication for its administration. In this study, we aim to investigate the necessity of routine flumazenil use after administering remimazolam for intravenous anesthesia.
Trial Details
NCT Number NCT05939674
Lead Sponsor Pusan National University Yangsan Hospital
Conditions
(from sponsor)		 Flumazenil Adverse Reaction, Remimazolam, Hip Joint, Elderly Patients
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov